CCM
EPRS

Consonance Capital Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Consonance Capital Management’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,324,669
Closed -$10.3M – 31
2015
Q3 		$10.3M Buy
2,324,669
+58,681
+3% +$345K 1.45% 14
2015
Q2 		$12.9M Buy
2,265,988
+742,215
+49% +$5.07M 1.3% 16
2015
Q1 		$13.6M Buy
+1,523,773
New +$12.2M 1.24% 19

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Consonance Capital Management's EPRS Position: Q4 2015 in Review

Consonance Capital Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q4 2015, closing a stake of 2,324,669 shares — an estimated $10.3M sold.

Consonance Capital Management first reported a position in EPRS in Q1 2015 and held it in 3 quarters. The position peaked at $13.6M in Q1 2015. 45 funds tracked by Wall St. Rank hold EPRS as of Q4 2015.

  • Consonance Capital Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q4 2015 after selling out during the quarter.
  • Consonance Capital Management sold 2,324,669 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q4 2015, an estimated $10.3M.
  • Consonance Capital Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 3 quarters.
  • Consonance Capital Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $13.6M in Q1 2015.
  • 45 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q4 2015.

Based on Consonance Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.